Research and Innovations Committee a new outlook for the European Association of Cardiovascular Imaging

The cardiovascular imaging is changing fast. New technologies, new practices are facing an important rise in the cost of cardiovascular imaging.1 To be recommended in the guidelines,2 new therapeutic agents or devices must have been validated in large observational studies or regis-tries and, even better, in randomized studies. This has been the case for cardiac resynchroni-zation therapy as well as for recent pharmaco-logical agents. We have not yet such exigency for imaging techniques but it might evolve in the near future. However, it exists an increasing necessity to demonstrate that our main imaging techni